Trial Profile
A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Fevipiprant (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 31 Jan 2021 This trial has been completed in France, according to European Clinical Trials Database.
- 25 Mar 2020 This trial has been Discontinued in Germany according to European Clinical Trials Database record.
- 22 Mar 2020 This trial has been completed in Greece, according to European Clinical Trials Database.